Company Page

Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company engineers synthetic gene circuits into medicines with enhanced precision and control to target difficult-to-treat cancers. Its lead product SENTI-202 is a first-in-class Logic Gated CAR NK cell therapy for acute myeloid leukemia that selectively targets cancer cells while sparing healthy bone marrow. The company's Gene Circuit technology platform enables cells to sense inputs, compute decisions, and respond to their cellular environments.

Company Founded in 2016

Healthtech & Biotech